Kornimate/medical-research-clean huggingface dataset:
acupuncture for infectious mononucleosis trial

Conditions: Infectious Mononucleosis

Summary: the purpose of this study is to investigate feasibility issues related to conducting an acupuncture study in a population of adolescents and young adults with infectious mononucleosis. additionally, this study will provide preliminary data regarding treatment parameters (acupuncture and standard care) and outcomes (i.e. fatigue).

this study examines the feasibility of treating adolescents and young adults diagnosed with infectious mononucleosis with acupuncture. additionally, this study will provide preliminary data regarding treatment parameters (acupuncture and standard care) and outcomes (i.e. fatigue).

Eligibility criteria:
inclusion criteria: * mono diagnosis confirmed by lab test * 21 days or less between start of symptoms and diagnostic test * presence of fatigue of at least 4/11 (by chalder fatigue questionnaire) * no other illnesses present * meets residency requirement exclusion criteria: * insufficient communication in english * unable to begin acupuncture within 21 days of diagnostic test * acupuncture use currently or in the preceding 3 months * currently under the care of a tcm practitioner * unwilling to be randomized

Keywords: infectious mononucleosis, mono, acupuncture
effect of transcutaneous auricular vagus nerve stimulation on pregnancy outcomes of infertility patients undergoing in vitro fertilization

Conditions: Infertility Assisted Reproductive Technology

Summary: the goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (tavns) enhance outcomes of in vitro fertilization (ivf). it will also learn about the safety of tavns. the main questions it aims to answer are: does tavns improve the clinical pregnancy rate of infertility patients undergoing ivf? what medical problems do participants have when using the tavns device? researchers will compare the tavns to the sham transcutaneous auricular vagus nerve stimulation (a look-alike device that produces a sub-threshold therapeutic stimulus and functions as a sham stimulus) and blank control to see if the tavns device works to enhance outcomes of ivf. participants will: use the device a total of 2 hours daily, with the sessions divided into four parts, each lasting 30 minutes. at least one of these periods occur within 2 hours before bedtime. visit the clinic according to the scheduled treatment time points of ivf. keep a diary of their adverse events and the number of times they use the device


Eligibility criteria:
inclusion criteria: 1. subjects aged 20 to 40 years, diagnosed with infertility, and preparing to undergo ivf treatment; 2. female subjects with anti-müllerian hormone (amh) \> 1.2 ng/ml; 3. scoring at mild-to-moderate levels of impairment on anxiety, and depression scales; 4. both the subject and their family sign the informed consent form. exclusion criteria: 1. the subject had been treated with tavns in the past; 2. subjects preparing to undergo frozen embryo transfer; 3. subjects with a history of mental disorder or who score at a severe level of impairment on anxiety and depression scales; 4. taking sedatives, anxiety, depression, or psychiatric medications; 5. comorbidities including arrhythmia, hypertension, diabetes, chronic heart and kidney diseases; 6. ineligibility for enrollment assessed by a gynecologist or neurologist; 7. mri contraindications; 8. metallic implants or devices contraindicating tavns.

Keywords: infertility assisted reproductive techniques transcutaneous auricular vagus nerve stimulation
skills-training for reducing risky alcohol use in app form

Conditions: Alcohol Abuse; Alcohol Use Disorder; Alcohol Drinking; Alcohol Dependence; Alcohol; Harmful Use

Summary: this study evaluates the efficacy of a skills training web-based mobile phone application, telecoach among individuals in the general population seeking help for their risky alcohol consumption on the internet. the design is a two-armed randomized controlled design, and outcomes are measured in terms of changes in excessive alcohol use at follow up 6, 12 and 26 weeks after study initiation and baseline data gathering. the telecoach web app delivers skills training in the form of exercises commonly used in psychosocial interventions for risky alcohol use. the controll condition is a web app providing information on the effects of alcohol on the consumers' health.

this study evaluates the efficacy of a skills training web-based mobile phone application, telecoach among individuals in the general population seeking help for their risky alcohol consumption on the internet. the design is a two-armed randomized controlled design, and outcomes are measured in terms of changes in excessive alcohol use at follow up 6, 12 and 26 weeks after study initiation and baseline data gathering. individuals seeking help for problematic alcohol use on the internet will get access to a webpage with information about the study. individuals leaving informed consent are asked to fill out questionnaires about alcohol use, depression, anxiety and information on gender and weight. those with excessive alcohol use (\>14 standard glasses/week for men and \> 9 for women) are randomized into one of two groups: 1. access to the telecoach web-app and 2. access to a control condition with an information-providing web-app. outcomes on alcohol use are gathered by electronic self-registration at 6, 12 and 26 weeks after study initiation. additional questions on the users' satisfaction with the app assigned to them and other support for problematic alcohol used during the research period at 26 weeks. the telecoach web-app is a skills-training app developed for use on a mobile smart-phone. the skills-training components are common to psychosocial treatment protocols for problematic alcohol consumption. the control condition web-app is a simple text-based app providing information on the effects of alcohol on the consumers' health. outcomes will be reported, analyzed and discussed in a scientific article.

Eligibility criteria:
inclusion criteria: * ≥ 18 years * risky alcohol consumption defined as alcohol use disorders identification test (audit) scores of ≥6 points for women and ≥ 8 points for men. exclusion criteria: * severe depression, defined as a madrs-s score of \> 30 * sucide risk, defined as a madrs-s, item 9 (lust for life) score \> 4 * drug abuse, defined as a score of ≥ 8 on the dudit

Keywords: randomized controlled trial internet mobile phone smartphone app alcohol substance use
measured vs navigated techniques in total hip arthroplasty

Conditions: Osteoarthritis, Hip

Summary: accurate reconstruction of the native hip parameters following total hip arthroplasty is associated with improved outcome. in order to improve ability for optimum reconstruction, 3-d templating software can be utilized that provide detailed information regarding native anatomy. in order to achieve reconstruction within acceptable parameters as per pre-operative plan, some surgeons propose the use of intra-operative devices that measure component orientation and joint reconstruction ("measured-tha"), whilst others propose the use of navigation tools ("navigation-tha). both techniques have shown superiority compared to the most commonly used "freehand" technique, but no prior study has assessed for superiority between these 2 techniques. furthermore, to-date assessment of post-operative reconstruction has not been tested in detail as post-tha assessments are based on radiographs which provide incomplete, 2-dimensional, assessments and are lacking the important axial plane reconstruction parameters. the aims of this prospective, randomized, trial are to 1. appraise the ability to achieve the pre-operative 3-d plan (as per formuslab) through a comparison of pre-op plan to post-operative reconstruction; 2. compare ability to accurately reconstruct hip following tha between "navigated-" (intellijoint®) and "measured-" techniques; and in doing so it will also 3. assess the accuracy of the intra-operative assessments of reconstruction through a comparison of objective (i.e. measured) intra-operative assessments with the post-operative reconstructions achieved.


Eligibility criteria:
inclusion criteria: * patients who are signed for a tha for primary or secondary osteoarthritis without overt deformity that would require revision type implants and with good enough bone quality to be listed for uncemented component implantation. exclusion criteria: * secondary oa due to dysplasia (hartofilakidis \>1) * avascular necrosis of the hip with destruction of joint structure * sequelae of pediatric deformity with abnormal anatomy * cemented fixation of femur or acetabulum * previous arthroplasty-type procedure * previous septic arthritis of the hip
epidemiological multicohort study of latent covid-19 infections

Conditions: COVID-19

Summary: cross-sectional study to detect latent covid-19 infections in residents and staff of old people's and nursing homes in the city of solingen with a prospective follow-up of 6 months in a subgroup.

particular interest is being paid to old people's and nursing homes during the covid-19 pandemic, as people at particular risk are to be found there. therefore, the health department of the city of solingen will carry out extensive testing of both staff and residents for covid-19 in this sensitive area. the scientific institute bethanien für pneumologie e.v. would like to collect and evaluate the data and test results collected in the process in order to record the occurrence of infections in this area and to obtain information on possible routes of infection and the effectiveness of hygiene measures taken. the aims of the study are: 1. prevalence of latent covid-19 infections at one point in time among residents and staff of old people's and nursing homes in solingen. 2. prevalence of latent covid-19 infections over a period of 6 months among staff of a single nursing home (=subgroup) 3. analysis of transmission pathways of the virus in a nursing home 4. analysis of the effectiveness of hygiene measures taken 5. analysis of risk factors (previous illnesses, medication, etc.)

Eligibility criteria:
inclusion criteria: * informed consent of the test person or the legally authorised guardian exclusion criteria: * missing consent
a placebo controlled safety and efficacy study of msdc-0160 in type 2 diabetes with active comparator

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to determine if msdc-0160 is effective in the treatment of type 2 diabetes.


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes naive or on metformin * male and female (postmenopausal or surgically sterilized), 18 to 70 years of age. exclusion criteria: * use of diabetes medications other than metformin. * history of heart failure or previous myocardial infarction. * blood pressure great than 160/100 mmhg.
testosterone replacement in metabolic syndrome and inflammation

Conditions: Hypogonadism; Metabolic Syndrome; Obesity; Erectile Dysfunction

Summary: hypogonadism (hg) frequently complicates the metabolic syndrome (mets), whether testosterone replacement (trt) is beneficial has not been clearly ascertained. this study was designed to address the effects of trt on insulin resistance, body composition and pro-inflammatory status in naïve patients with mets and hg.

the features of metabolic syndrome (mets) include abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance or glucose intolerance. these symptoms are also frequently found in hypogonadal men. adipose tissue and androgens in male obesity are reciprocally linked. total and free testosterone (t) are decreased in proportion to the degree of body fatness while t regulates insulin sensitivity and body composition. as a consequence, hypoandrogenism carries an additional independent risk for cardiovascular and metabolic disorders. men with type 2 diabetes mellitus (t2d) exhibit lowered t levels that are inversely correlated to hba1c. in addition, abdominal adiposity causes an impairment of testicular steroidogenesis that is directly linked to circulating adipokines; enhanced cytokine release from macrophage-infiltrated adipose tissue is pivotal to the pathogenesis of insulin resistance and atherosclerosis. both mets and t2d share with hypogonadism such a proinflammatory state. for this reason we performed a randomized controlled trial on the effects of trt on insulin resistance and circulating inflammatory markers in a cohort of middle-aged men with mild hypogonadism and mets at first diagnosis, that were not taking medications known to influence the investigated outcomes. we established strict criteria for enrollment and used a physiological replacing therapy. given that testosterone replacement therapy (trt) determines a reduction of body fat mass paralleled by an increase in fat free mass (6), and that trt exerts an anti-inflammatory role inhibiting interleukins (il), in particular the il-6 gene (14), it remains to be established whether these independent effects also reflect in an improvement in insulin resistance.

Eligibility criteria:
inclusion criteria: * patients with metabolic syndrome according to atpiii * patients with mild hypogonadism (both testosterone evaluations between 6 and 11 nmol/l) * patients naïve to hypoglycemic therapies exclusion criteria: * patients on hypoglycemic medications * patients with severe hypogonadism (\<5 nmol/l) * patients with borderline t values hypogonadism (\>11 nmol/l) * patients with contraindication to testosterone therapy: prostate cancer, psa\>4 ng/ml, severe hepatic or renal insufficiency, hb\>17, htc\>52%, severe urinary retention

Keywords: adiponectin resistin adipocytes testosterone aging homa-ir insulin hypogonadism metabolic syndrome obesity erectile dysfunction
efficacy of dcvac/ovca plus standard of care in relapsed platinum resistant epithelial ovarian carcinoma

Conditions: Epithelial Ovarian Carcinoma

Summary: the purpose of this study is to determine whether dcvac/ovca added to chemotherapy may result in prolongation of overall survival (os).

the purpose of this study is to determine whether dcvac/ovca added to standard of care chemotherapy may result in prolongation of overall survival (os).

Eligibility criteria:
inclusion criteria: * females 18 years or older * histologically confirmed international federation of gynecology and obstetrics (figo) stage iii or iv epithelial ovarian, primary peritoneal, or fallopian tube carcinoma (serous, endometrioid or mucinous), who have undergone initial surgery or interval debulking surgery but have not reached complete remission of more than 6 months after first line platinum based chemotherapy, for one of the following reasons * patients are platinum-refractory (no response) * complete remission was not reached (partial responders) * relapse within ≤6 months of remission (platinum-resistant) * platinum-based chemotherapy failure should have been confirmed by computerized tomography (ct)/magnetic resonance imaging (mri) scan (platinum-resistant) or by finding described as 'did not reach complete clinical remission' (platinum-refractory or platinum-partial response) patients must have at least one measureable target lesion as defined by the response evaluation criteria in solid tumors (recist) 1.1 criteria * eastern cooperative oncology group (ecog) performance status 0-2 exclusion criteria: * figo i,ii epithelial ovarian cancer * figo iii, iv clear cells epithelial ovarian cancer * non-epithelial ovarian cancer * borderline tumors (tumors of low malignant potential) * prior or current systemic anti-cancer therapy for ovarian cancer \[for example chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy, vascular endothelial growth factor (vegf) therapy or hormonal therapy\] except first line platinum-based chemotherapy (with or without bevacizumab) * previous radiotherapy to the abdomen and pelvis * malignancy other than epithelial ovarian cancer, except those that have been in clinical remission (cr) for a minimum of 3 years, and except carcinoma in-situ of the cervix or non-melanoma skin carcinomas * clinically significant cardiovascular disease * active autoimmune disease requiring treatment * history of severe forms of primary immune deficiencies * systemic immunosuppressive therapy for any reason

Keywords: immunotherapy serous relapsed platinum resistant (pt) ovarian cancer (ovca) biological vaccine
effect of suprascapular nerve block and axillary nerve block after arthroscopic rotator cuff repair

Conditions: Rotator Cuff Tears

Summary: the goal of this clinical trial is to verify the effect of suprascapular nerve block and axillary nerve block in relieving postoperative pain after arthroscopic rotator cuff repair. are there differences in visual analog pain scale and patient's satisfaction? are there differences in mean plasma pain related cytokines? the participants will undergo preemptive ultrasound guided suprascapular nerve block and axillary nerve block using each 0.75% ropivacaine 10ml or each 0.9% saline 10ml.


Eligibility criteria:
inclusion criteria: * a definite rotator cuff tear that needed repair seen on preoperative magnetic resonancce imaging (mri) * acceptance of arthroscopic surgery including rotator cuff repair * age same as or more than 20 years * acceptance of preemptive regional block and pca, and blood testing exclusion criteria: * did not undergo arthroscopic rotator cuff repair * stopped pca before 48 hours postoperatively because of associated side effects * a history of previous ipsilateral shoulder operation or fracture * a concomitant neurologic disorder around the shoulder * a failure of blood sampling including hemolysis, etc.

Keywords: suprascapular nerve block(ssnb) axillary nerve block(anb) visual analog pain scale(vas) patient's satisfaction(sat) pain related cytokines arthroscopic rotator cuff repair
a real-world wearables study in fabry disease.

Conditions: Fabry Disease

Summary: despite improvements in fabry disease care in recent years, many patients still have poor outcomes. in addition to the many physical symptoms that patients can experience, the disease also places individuals at an increased risk of mental health conditions, such as anxiety and depression. low physical activity levels and increased sedentary time are detrimentally associated with anxiety, depression and quality of life in the general population. currently, no such research has been conducted in individuals with fabry disease. data will consist of: (1) information from hospital medical records, (2) patient reported outcomes collected via questionnaires, and (3) measurements from a clinical-grade wearable device. individuals with fabry disease aged 18 years or above will be considered for eligibility screening.

trial assessments: baseline questionnaires baseline questionnaires will include the hospital anxiety and depression scale (hads) and the euroqol 5-dimension questionnaire (eq-5d-5l). this will be administered via qualtrics. thigh-worn device (activpal) participants will attach the activpal device to their anterior thigh for 8 days and continue their usual daily behaviour throughout the week. this will measure sitting, standing, stepping and sleep time. this device is accompanied by a hard copy daily diary, where participants will be asked to input the time they wake up, they get out of bed, they get into bed, and when they go to sleep. clinical data data from medical records will include disease phenotype and clinical severity including mutation type, lyso-gb3, left ventricular mass index and diastolic dysfunction. such data will be sourced from electronic patient records. mainz severity score index, and its age-adjusted score will be calculated from data on electronic patient records. these will be collected retrospectively from the previous 12 months upon enrolment.

Eligibility criteria:
inclusion criteria: * diagnosis of fabry disease documented by genotyping and/or enzymatic analysis. * resident in the uk. * aged 18 years and over. * capable of providing informed consent. * physically able to stand and ambulate independently. exclusion criteria: * a known allergy to any materials in the wearable device. * not able to have or use a wearable. * taking part in an interventional study which would preclude real-world data collection. * unable to communicate in english to a sufficient level to permit engagement in the study.
socially assistive robots for interaction with older adults with dementia

Conditions: Alzheimer Disease

Summary: a 12-month pilot study will be comprised of two groups of people diagnosed with mild alzheimer's disease and related dementia for a total of 80 senior subjects. subjects will be randomly assigned to two groups: group 1 users will play games with and administered by ryan, 2-3 times a week and 30-minutes per day. group 2 (active control group) will play solitary games and activities but will have to interaction with ryan. the team will measure the changes and improvement in the social/emotional well-being of these two groups and eventual changes in the cognitive/memory functions of elderly people living in the similar environment.


Eligibility criteria:
inclusion criteria * age ≥ 65 years * early alzheimer's disease and related dementia diagnosed by a qualified provider * saint louis university mental status (slums) score between 10 and 25 * resident of assisted living facility for at least one month prior and for the duration of the study * deemed conditioned enough to participate in physical activities after a wellness check * verbal skill to interact * participant or legal decision exclusion criteria: aggressive behavior * diagnosed with severe dementia or memory loss * acute physical illness that impairs ability to participate * patients with serious comorbidity, tumors and other diseases casually related to cognitive impairment * history of alcohol or drug abuse, head trauma, psychoactive substance use and other causes of memory impairment * significant sensory impairment